Advertisement

Drug Safety

, Volume 29, Issue 10, pp 889–896 | Cite as

Evidence of Tendinitis Provoked by Fluoroquinolone Treatment

A Case-Control Study
  • Giovanni CorraoEmail author
  • Antonella Zambon
  • Lorenza Bertù
  • Anna Mauri
  • Valentina Paleari
  • Camillo Rossi
  • Mauro Venegoni
Original Research Article

Abstract

Objective: To investigate the association between the use of fluoroquinolone agents and the risk of tendinitis in a large population-based case-control study.

Methods: The study was performed by linking automated health databases from the Region of Lombardia, Italy. Cases were patients aged ≥18 years who had a hospital discharge diagnosis of non-traumatic tendinitis in 2002–3. For each case, up to five controls were randomly selected among those eligible for inclusion in the study. A conditional logistic regression model was used to estimate the odds ratio of tendinitis associated with the current, recent and past use of fluoroquinolones. Odds ratios were adjusted for exposure to other antibacterials and other drugs.

Results: 22 194 cases and 104 906 controls met the inclusion criteria. Current use of fluoroquinolones significantly increased the risk of tendon disorders as a whole (odds ratio [OR] = 1.7; 95% CI 1.4, 2.0), tendon rupture (OR = 1.3; 95% CI 1.0, 1.8) and rupture of the Achilles’ tendon (OR = 4.1; 95% CI 1.8, 9.6). Concomitant use of corticosteroids and fluoroquinolones increased the risk of both tendon rupture (OR = 3.1; 95% CI 1.5, 6.3) and rupture of the Achilles’ tendon (OR = 43.2; 95% CI 5.5, 341.1).

Discussion: Evidence that exposure to fluoroquinolones is associated with the sudden occurrence of tendinitis is supported by this large population-based study. We can estimate that a single case of rupture of the Achilles’ tendon would occur for every 5958 persons treated with fluoroquinolones (95% CI 2148, 23 085). The corresponding number needed to harm is 979 (95% CI 122, 9172) for patients who concomitantly use corticosteroids and 1638 (95% CI 351, 8843) for those aged >60 years.

Conclusion: Clinicians should be aware of this adverse effect, and the increased risk for fluoroquinolone-associated tendinitis in elderly patients with corticosteroid use must be considered when these agents are prescribed.

Keywords

National Health Service Fluoroquinolones Index Date Tendon Rupture Tendinitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Support for this study came from grants from the Italian Minister of the University and Research (“Fondo d’Ateneo per la Ricerca” portion, year 2005, and PRIN portion, protocol no. 2005068001, year 2005). The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384–94PubMedCrossRefGoogle Scholar
  2. 2.
    Lietman PS. Fluoroquinolone toxicities: an update. Drugs 1995; 49Suppl. 2: 159–63PubMedCrossRefGoogle Scholar
  3. 3.
    Ball P, Mandell L, Niki Y, et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999; 21: 407–21PubMedCrossRefGoogle Scholar
  4. 4.
    Bailey RR, Kirk JA, Peddie BA. Norfloxacin induced rheumatic disease [letter]. N Z Med J 1983; 96: 590PubMedGoogle Scholar
  5. 5.
    McEwan SR, Davey PG. Ciprofloxacin and tenosynovitis [letter]. Lancet 1988; II: 900CrossRefGoogle Scholar
  6. 6.
    Franck JL, Bouteiller G, Chagnaud P, et al. Rupture des tendons d’Achille chez deux adultes traites par pefloxacine dont un cas bilateral. Rev Rhum Mal Osteoartic 1991; 58: 904PubMedGoogle Scholar
  7. 7.
    Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Engl J Med 1994; 331: 748PubMedCrossRefGoogle Scholar
  8. 8.
    Le Huec JC, Schaeverbeke T, Chauveaux D, et al. Epicondylitis after treatment with fluoroquinolone antibiotics. J Bone Joint Surg Br 1995; 77: 293–5PubMedGoogle Scholar
  9. 9.
    McGarvey WC, Singh D, Trevino SG. Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: a case report and literature review. Foot Ankle Int 1996; 17: 496–8PubMedGoogle Scholar
  10. 10.
    Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20PubMedGoogle Scholar
  11. 11.
    Movin T, Gad A, Guntner P, et al. Pathology of the Achilles tendon in association with ciprofloxacin treatment. Foot Ankle Int 1997; 18: 297–9PubMedGoogle Scholar
  12. 12.
    West MB, Gow P. Ciprofloxacin, bilateral Achilles tendonitis and unilateral tendon rupture. N Z Med J 1998; 111: 18–9PubMedGoogle Scholar
  13. 13.
    Gold L, Igra H. Levofloxacin-induced tendon rupture: a case report and review of the literature. J Fam Pract 2003; 16: 458–60CrossRefGoogle Scholar
  14. 14.
    Davey PG, Bax RP, Newey J, et al. Growth in the use of antibiotics in the community in England and Scotland in 1980-93. BMJ 1996; 312: 613PubMedCrossRefGoogle Scholar
  15. 15.
    Bremon AR, Ruiz-Tovar M, Gorricho BP, et al. Non-hospital consumption of antibiotics in Spain: 1987-1997. J Antimicrob Chemother 2000; 45: 395–400PubMedCrossRefGoogle Scholar
  16. 16.
    Van der Linden PD, Nab HW, Simonian S, et al. Fluoroquinolone use and the change in incidence of tendon rupture in the Netherlands. Pharm World Sci 2001; 23: 89–92PubMedCrossRefGoogle Scholar
  17. 17.
    Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Therapie 1994; 49: 75–6PubMedGoogle Scholar
  18. 18.
    Pierfitte C, Gillet P, Royer RJ. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193PubMedCrossRefGoogle Scholar
  19. 19.
    Ribard P, Audisio F, Kahan MF, et al. Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 1992; 19: 1479–81PubMedGoogle Scholar
  20. 20.
    Meyboom RH, Olsson S, Knol A, et al. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivatives. Pharmacoepidemiol Drug Saf 1994; 3: 185–9CrossRefGoogle Scholar
  21. 21.
    Zabraniecki L, Negrier I, Vergne P, et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol 1996; 23: 516–20PubMedGoogle Scholar
  22. 22.
    Van der Linden PD, Puijenbroek EPV, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Care Res 2001; 45: 235–9CrossRefGoogle Scholar
  23. 23.
    Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian Regions. Drug Saf 2003; 26: 109–20PubMedCrossRefGoogle Scholar
  24. 24.
    Donck JB, Segaert MF, Vanrenterghem YF. Fluoroquinolones and Achilles tendinopathy in renal transplant recipients. Transplantation 1994; 58: 736–7PubMedGoogle Scholar
  25. 25.
    Melhus A. Fluoroquinolones and tendon disorders. Expert Opin Drug Saf 2005; 4: 299–309PubMedCrossRefGoogle Scholar
  26. 26.
    Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 1995; 332: 193PubMedCrossRefGoogle Scholar
  27. 27.
    Committee on Safety of Medicines. Tendon damage associated with quinolone antibiotics. Curr Probl Pharmacovigilance 1995; 21: 8Google Scholar
  28. 28.
    ADRAC. Tendinitis and tendon rupture with fluoroquinolones. Aust Adv Drug React Bull 1999; 18: 10Google Scholar
  29. 29.
    Stahlmann R, Lode H. Toxicity of quinolones. Drugs 1999; 58Suppl. 2: 37–42PubMedCrossRefGoogle Scholar
  30. 30.
    Shakibaei M, de Souza P, van Sickle D, et al. Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. Arch Toxicol 2001; 75: 369–74PubMedCrossRefGoogle Scholar
  31. 31.
    Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97–102PubMedCrossRefGoogle Scholar
  32. 32.
    Sendzik J, Shakibaei M, Schafer-Korting M, et al. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005; 212: 24–36PubMedCrossRefGoogle Scholar
  33. 33.
    Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433–7PubMedCrossRefGoogle Scholar
  34. 34.
    Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: a case-control study. BMJ 2002; 324: 1306–7PubMedCrossRefGoogle Scholar
  35. 35.
    Van der Linden PD, Sturkenboom MC, Herings RM, et al. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in the elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801–7PubMedCrossRefGoogle Scholar
  36. 36.
    Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. Epub 2006 Feb 3Google Scholar
  37. 37.
    Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Scientific Publications no. 32. Lyon: International Agency for Research on Cancer, 1980Google Scholar
  38. 38.
    Leppilahti J, Puranen J, Orava S. Incidence of Achilles tendon rupture. Acta Orthop Scand 1996; 67: 277–9PubMedCrossRefGoogle Scholar
  39. 39.
    Leppilahti J, Orava S. Total Achilles tendon rupture: a review. Sports Med 1998; 25: 79–100PubMedCrossRefGoogle Scholar
  40. 40.
    Maffulli N. Rupture of Achilles tendon. J Bone Joint Surg Br 1999; 81-A(7): 1019–36Google Scholar
  41. 41.
    Waterston SW, Maffulli N, Ewen SW. Subcutaneous rupture of the Achilles tendon: basic science and some aspects of clinical practice. Br J Sports Med 1997; 31: 285–98PubMedCrossRefGoogle Scholar
  42. 42.
    Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433–7PubMedGoogle Scholar
  43. 43.
    Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105: 488–95PubMedGoogle Scholar
  44. 44.
    Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996; 41: 277–84PubMedCrossRefGoogle Scholar
  45. 45.
    Gravlee JR, Hatch RL, Galea AM. Achilles tendon rupture: a challenging diagnosis. J Am Board Farm Pract 2000; 13: 371–3Google Scholar
  46. 46.
    Rask MR. Achilles tendon rupture owing to rheumatoid disease: case-report with a nine-year follow-up. JAMA 1978; 239: 435–6PubMedCrossRefGoogle Scholar
  47. 47.
    Ford LT, DeBender L. Tendon rupture after local steroid injection. South Med J 1979; 72: 827–30CrossRefGoogle Scholar
  48. 48.
    Kleinman M, Gross AE. Achilles tendon rupture following steroid injection: report of three cases. J Bone Joint Surg Am 1983; 65: 1345–7PubMedGoogle Scholar
  49. 49.
    Dikey W, Patterson V. Bilateral Achilles tendon rupture simulating peripheral neuropathy: unusual complication of steroid therapy. J R Soc Med 1987; 80: 386–7Google Scholar
  50. 50.
    Newnham DM, Douglas JG, Legge JS, et al. Achilles tendon rupture: an underrated complication of corticosteroid treatment. Thorax 1991; 46: 853–4PubMedCrossRefGoogle Scholar
  51. 51.
    Hersh BL, Heath NS. Achilles tendon rupture as a result of oral steroid therapy. J Am Podiatr Med Assoc 2002; 92: 355–8PubMedGoogle Scholar
  52. 52.
    Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: “the number of patients needed to be treated for one additional patient to be harmed”. BMJ 2000; 320: 503–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Giovanni Corrao
    • 1
    Email author
  • Antonella Zambon
    • 1
  • Lorenza Bertù
    • 1
  • Anna Mauri
    • 1
  • Valentina Paleari
    • 1
  • Camillo Rossi
    • 2
  • Mauro Venegoni
    • 3
  1. 1.Unit of Biostatistics and Epidemiology, Department of StatisticsUniversity of Milan-BicoccaMilanItaly
  2. 2.Local Health DepartmentProvince of ComoLombardia RegionItaly
  3. 3.Lombardia Centre of PharmacovigilanceMilanItaly

Personalised recommendations